Paroxetine for social anxiety and alcohol use in dual‐diagnosed patients

@article{Randall2001ParoxetineFS,
  title={Paroxetine for social anxiety and alcohol use in dual‐diagnosed patients},
  author={Carrie L. Randall and Michael R. Johnson and Angelica K. Thevos and Susan C. Sonne and Suzanne Elizabeth Thomas and Shauna L. Willard and Kathleen T. Brady and Jonathan R. Davidson, M.D.},
  journal={Depression and Anxiety},
  year={2001},
  volume={14}
}
The objective of this study was to compare the efficacy and tolerability of paroxetine to matched placebo in adults with co‐occurring social anxiety disorder and alcohol use disorder. Outcome measures included standardized indices of social anxiety and alcohol use. Fifteen individuals meeting DSM‐IV criteria for both social anxiety disorder and alcohol use disorder were randomized to treatment. Paroxetine (n = 6) or placebo (n = 9) was given in a double‐blind format for 8 weeks using a flexible… 
Paroxetine reduces social anxiety in individuals with a co-occurring alcohol use disorder.
A complex relationship between co-occurring social anxiety and alcohol use disorders: what effect does treating social anxiety have on drinking?
TLDR
Successfully treating social anxiety symptoms with paroxetine does not reduce drinking in dual-diagnosed individuals who are not seeking treatment for alcohol problems, but paroxETine does reduce reliance on alcohol to engage in social situations, and may change the reasons why one drinks.
Levetiracetam for the Treatment of Co-Occurring Alcohol Dependence and Anxiety: Case Series and Review
  • J. Mariani, F. Levin
  • Medicine, Psychology
    The American journal of drug and alcohol abuse
  • 2008
TLDR
Pre-clinical and clinical evidence suggests that levetiracetam, a newer generation anticonvulsant medication, may be efficacious in the treatment of co-occurring alcohol use and anxiety disorders.
Treatment of Comorbid Alcohol Dependence and Anxiety Disorder: Review of the Scientific Evidence and Recommendations for Treatment
TLDR
Selective serotonin reuptake inhibitors (SSRIs), especially sertraline, showed effective results in posttraumatic stress disorder and in comorbid AnxD–AUD, and buspirone, gabapentin, and pregabalin were found to be effective in comorsical AnxDs–AUD.
The impact of comorbid anxiety and depression on alcohol treatment outcomes.
TLDR
This study examines the impact of comorbid Diagnostic and Statistical Manual version IV (DSM-IV) anxiety and/or depression on out-patient treatment for alcohol problems and determines the most appropriate model of care for alcohol treatment seekers withComorbid DSM-IV anxiety and-or depression.
Evidence-Based Pharmacotherapy for Mood and Anxiety Disorders with Concurrent Alcoholism
  • K. Brady
  • Medicine, Psychology
    CNS Spectrums
  • 2008
TLDR
Failure to treat a concurrent psychiatric disorder reduces the likelihood that the treatment for a substance use disorder (SUD) will be effective, and the effects of nontreatment were demonstrated in a prospective study assessing alcohol-dependent patients for 1 year following hospitalization for alcohol dependence.
Pharmacotherapy for social anxiety disorder: a systematic review
TLDR
Taken together, trials of selective serotonin reuptake inhibitors and serotonin–norepinephrine reptake inhibitors provide the largest evidence base for agents that are both effective and well tolerated.
Clinical practice guideline on pharmacological and psychological management of adult patients with an Anxiety Disorder and comorbid substance use.
This review synthesizes the pharmacological and psychosocial interventions that have been conducted in comorbid anxiety disorders and SUDs while also providing clinical recommendations about which
Pharmacotherapy for anxiety and comorbid alcohol use disorders.
TLDR
There was very low quality evidence for an effect of paroxetine on global clinical response to treatment, as assessed by the Clinical Global Impressions - Improvement scale (CGI-I).
...
...

References

SHOWING 1-10 OF 40 REFERENCES
Paroxetine treatment of generalized social phobia (social anxiety disorder): a randomized controlled trial.
TLDR
Paroxetine is an effective treatment for patients with generalized social phobia and short-term treatment results in substantial and clinically meaningful reductions in symptoms and disability.
Cognitive-behavioral and pharmacological treatments of social phobia. A controlled study.
Sixty-five patients with social phobia were treated in a study that compared a cognitive-behavioral group treatment program with pharmacotherapy with alprazolam, phenelzine sulfate, or pill-placebo
Treatment of social phobia with gabapentin: a placebo-controlled study.
TLDR
It seems that gabapentin offers a favorable risk-benefit ratio for the treatment of patients with social phobia, and further studies are required to confirm this effect and to determine whether a dose-response relationship exists.
Nefazodone in social phobia.
TLDR
Findings support a role for nefazodone in the treatment of social phobia, generalized type and controlled studies will be required to further investigate this preliminary finding.
Functional impairment in social phobia.
TLDR
Social phobia is associated with impairment in most areas of functioning, and the new scales appear useful in assessing functional impairment related to social phobia.
Placebo-controlled trial of moclobemide in social phobia
TLDR
Moclobemide may have efficacy in the treatment of social phobia, but absence of significant differences on most primary outcome measures and small effect sizes for all outcome measures suggest that the magnitude of its clinical effect is small.
...
...